Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases

Launched by UNIVERSITY HOSPITAL, GRENOBLE · Apr 17, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases," is exploring new ways to treat inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, during flare-ups. These flare-ups can cause significant discomfort and affect a person's quality of life. The study aims to find a better approach to managing inflammation by using a technique that alters how certain immune cells, called monocytes, respond during these episodes. Researchers hope that this method will lead to treatments that are easier for patients to tolerate compared to current options, which can have serious side effects.

To participate in this trial, individuals must be 18 years or older and currently experiencing a severe flare-up of IBD that requires hospitalization or a special examination called an endoscopy. It's important to note that individuals who are pregnant, breastfeeding, or have certain health conditions (like active infections) cannot participate. While the trial is not yet recruiting participants, it will provide those who qualify with a chance to explore a potentially innovative treatment approach for managing their IBD flare-ups.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women over 18
• • Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
• • Patient not objecting to the REPRO-MICI study
• Exclusion Criteria:
• • Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).
• • Patients with positive HIV, HBV or HCV serology.
• • Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.